1. Blood type does not modify prognosis in patients with COVID-19: experience in a COVID-19 hospital in Mexico
- Author
-
Elizabeth Mader-Maldonado, Adrián Santoyo-Sánchez, Emmanuel Bermeo-Maldonado, Adolfo Martínez-Tovar, Carlos Martínez-Murillo, Álvaro Cabrera-García, Ubaldo Valencia-Rocha, Carolina Balderas-Delgado, Christian Omar Ramos-Peñafiel, and Irma Olarte-Carrillo
- Subjects
Blood type ,Univariate analysis ,medicine.medical_specialty ,Multivariate analysis ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Hematology ,Emergency department ,Log-rank test ,Oncology ,Internal medicine ,ABO blood group system ,medicine ,In patient ,business - Abstract
Introduction: According to reports from China and Europe, there are various clinical and laboratory risk factors that associate with both death and the use of a ventilator in coronavirus disease 2019 (COVID-19). In Wuhan, blood type A was related to these complications, but this factor is unknown for Latin America. Objective was to describe the association of blood type with complications related to COVID-19 infection. Material and methods: A retrospective comparative study from the clinical files of patients cared for in the emergency department between April and May 2020. Results: Data was analyzed from 120 patients hospitalized with COVID-19 infection. There were no differences in age and gender by blood type. Type O was the most frequent (80.8%) followed by type A (11.7%) and type B (7.5%). In univariate analysis, there was no impact of blood type on survival, individually (groups A, B, O) (log rank 0.154). In multivariate analysis, only age influenced prognosis ( p =0.004). Above the risk, type O showed no impact on mortality (OR 1.0119, 95% CI: 0.3898–2.6272, p =0.980) or ventilator use (1.5616, 95% CI: 0.4834–5.0453, p =0.456), likewise for types A and B (OR 0.9882, 95% CI, 0.3806–2.5657). Conclusion: Blood type does not impact prognosis in Mexican patients with COVID-19.
- Published
- 2021